Abstract
COVID-19 is an acute respiratory disease that has been classified as a pandemic by the World Health Organization. Characterization of this disease is still in its early stages; however, it is known to have high mortality rates, particularly among individuals with preexisting medical conditions. Creating models to identify individuals who are at the greatest risk for severe complications due to COVID-19 will be useful for outreach campaigns to help mitigate the disease’s worst effects. While information specific to COVID-19 is limited, a model using complications due to other upper respiratory infections can be used as a proxy to help identify those individuals who are at the greatest risk. We present the results for three models predicting such complications, with each model increasing predictive effectiveness at the expense of ease of implementation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are employed by ClosedLoop.ai, which develops a healthcare data science platform and funded this effort.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data we used is the CMS Medicare LDS 5% sample for 2015-2016. We cannot distribute this data, but it is available for purchase to to qualified researchers working on projects for the benefit of Medicare beneficiaries.
